This S-3 enables Alpha Capital to convert and sell shares at a discount to market, creating persistent overhang. With only $2.2M cash and a going concern warning, the company will likely need to draw further on the $44M Additional Investment Right, which would trigger additional dilution at potentially lower prices. Monitor for conversion notices and subsequent 8-K filings reporting share issuances. The stock is at high risk of Nasdaq delisting if the bid price falls below $1.00.
Price Chart
Executive Summary
ENvue Medical filed an S-3 registration statement to register 6,000,768 shares of common stock for resale by Alpha Capital Anstalt, the company's sole institutional investor. These shares are issuable upon conversion of Series H Convertible Preferred Stock, which was issued under an Additional Investment Right that has already provided ~$5.6M in net proceeds. The company will not receive any proceeds from this resale registration. The filing coincides with the company's Q1 2026 10-Q, which shows cash of $2.2M, a working capital deficit, and an accumulated deficit, highlighting a precarious financial position.
Key Financial Metrics
Key Facts
- S-3 registers 6,000,768 shares for resale by Alpha Capital Anstalt, representing ~114% dilution relative to the 5,246,513 shares outstanding as of April 30, 2026
- Conversion price of Series H Preferred Stock is $1.0422 per share, well below the May 15, 2026 closing price of $1.095
- Company will not receive any proceeds from the resale; this is a pure dilution event for existing shareholders
- Q1 2026 cash balance was only $2.2M, down from $4.2M at year-end 2025, with a working capital deficit of ~$0.7M
- Auditor's report on the 2025 10-K included a going concern explanatory paragraph
- Alpha Capital Anstalt also holds 10,657 additional Series H shares convertible into 10,014,183 common shares (subject to 9.99% blocker), plus 37,880 Series X shares convertible into 1,125,963 common shares, plus warrants for 751,364 shares
- Company is under a 1-year Nasdaq panel monitor for compliance with the $2.5M equity rule and $1.00 bid price rule
- The Series H Certificate of Designations was amended on Jan 30, 2026 to remove the floor price on conversion, enabling further price declines
Financial Impact
Up to 6,000,768 new shares (114% dilution) registered for resale at a conversion price of $1.0422, representing ~$6.3M in potential selling pressure at current prices. Company has only $2.2M cash and is burning cash rapidly.
Risk Factors
- Massive dilution: 6M shares registered vs 5.2M outstanding; total potential dilution from all Alpha holdings exceeds 18M shares
- Cash runway: $2.2M cash at Q1 end with negative working capital; likely to need additional capital within 2-3 quarters
- Nasdaq delisting risk: company is on a 1-year panel monitor for equity and bid price rules; further dilution could push price below $1.00
- Going concern: auditor flagged substantial doubt about ability to continue as a going concern
- Downward conversion spiral: removal of floor price means further stock price declines will lower the conversion price, increasing dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-024231 |
| Exhibit: ex107.htm | 0001493152-26-024231 |
| Exhibit: ex5-1.htm | 0001493152-26-024231 |
| Exhibit: ex23-1.htm | 0001493152-26-024231 |
| Document: 0001493152-26-024231-index-headers.html | 0001493152-26-024231 |
| Document: 0001493152-26-024231-index.html | 0001493152-26-024231 |
| Document: 0001493152-26-024231.txt | 0001493152-26-024231 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $0.4900 | awaiting T+20 | — | $0.2501 (+48.96%) |
Sep 4, 2026 7w ago | EFFECT | $4.03 $1.03 | ▲ +74.44% | ▲ +75.04% | $0.2501 (+93.79%) |
Aug 31, 2026 8w ago | 8-K | $4.31 | awaiting T+20 | — | $0.2501 (−94.20%) |
Aug 12, 2026 10w ago | 8-K | $4.90 $3.57 | ▲ +27.08% | ▲ +25.19% | $0.2501 (+94.89%) |
Aug 10, 2026 11w ago | S-3 | $0.3982 $0.3033 | ▲ +23.82% | ▲ +22.76% | $0.2501 (+37.19%) |
Jul 10, 2026 15w ago | 8-K | $0.4578 $0.4140 | ▲ +9.57% | ▲ +12.75% | $0.2501 (+45.37%) |
Jun 3, 2026 20w ago | Press Release | $0.8600 $0.5200 | ▼ −39.53% | ▼ −38.53% | $0.2501 (−70.92%) |
May 29, 2026 21w ago | EFFECT | $0.9020 $0.5400 | ▲ +40.13% | ▲ +38.34% | $0.2501 (+72.27%) |
May 18, 2026 23w ago | S-3 | $0.9300 $0.7262 | ▲ +21.91% | ▲ +22.90% | $0.2501 (+73.11%) |
May 12, 2026 23w ago | Press Release | $1.24 $0.8530 | ▼ −31.21% | ▼ −29.48% | $0.2501 (−79.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers